HC Wainwright Analysts Increase Earnings Estimates for ADAP

Adaptimmune Therapeutics plc (NASDAQ:ADAP) – Stock analysts at HC Wainwright increased their FY2024 earnings per share estimates for shares of Adaptimmune Therapeutics in a research report issued to clients and investors on Thursday, November 14th. HC Wainwright analyst A. He now forecasts that the biotechnology company will post earnings of ($0.12) per share for the year, up from their prior estimate of ($0.30). HC Wainwright has a “Buy” rating and a $3.50 price objective on the stock. The consensus estimate for Adaptimmune Therapeutics’ current full-year earnings is ($0.19) per share. HC Wainwright also issued estimates for Adaptimmune Therapeutics’ FY2025 earnings at ($0.54) EPS, FY2026 earnings at ($0.42) EPS, FY2027 earnings at ($0.12) EPS and FY2028 earnings at $0.06 EPS.

Several other research firms have also recently commented on ADAP. Guggenheim lowered their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday. StockNews.com cut shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $3.16.

Adaptimmune Therapeutics Price Performance

Shares of NASDAQ ADAP opened at $0.60 on Monday. The stock has a market cap of $152.17 million, a P/E ratio of -2.70 and a beta of 2.26. The firm’s 50-day simple moving average is $0.87 and its 200 day simple moving average is $1.03. Adaptimmune Therapeutics has a fifty-two week low of $0.42 and a fifty-two week high of $2.05. The company has a quick ratio of 3.09, a current ratio of 3.85 and a debt-to-equity ratio of 0.62.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC boosted its position in shares of Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 98,581 shares in the last quarter. FMR LLC lifted its stake in Adaptimmune Therapeutics by 3.0% during the third quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock valued at $1,655,000 after purchasing an additional 50,419 shares during the last quarter. Baillie Gifford & Co. lifted its stake in Adaptimmune Therapeutics by 10.7% during the third quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock valued at $15,944,000 after purchasing an additional 1,626,657 shares during the last quarter. GSA Capital Partners LLP bought a new stake in Adaptimmune Therapeutics during the third quarter worth approximately $95,000. Finally, Fullcircle Wealth LLC acquired a new position in Adaptimmune Therapeutics in the third quarter worth approximately $33,000. 31.37% of the stock is currently owned by institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.